Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
Matthew B Yurgelun1, Elaine Hiller2, Judy E Garber3
1Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA matthew_yurgelun@dfci.harvard.edu.
Abstract
No abstract available in PubMed .


